WO1998053787A1 - Agent de decomposition du tissu adipeux utilisant des ondes ultra sonores - Google Patents
Agent de decomposition du tissu adipeux utilisant des ondes ultra sonores Download PDFInfo
- Publication number
- WO1998053787A1 WO1998053787A1 PCT/JP1998/000487 JP9800487W WO9853787A1 WO 1998053787 A1 WO1998053787 A1 WO 1998053787A1 JP 9800487 W JP9800487 W JP 9800487W WO 9853787 A1 WO9853787 A1 WO 9853787A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ultrasonic
- irradiation
- fat
- ultrasonic waves
- living body
- Prior art date
Links
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 208000008589 Obesity Diseases 0.000 claims abstract description 18
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 14
- 230000005540 biological transmission Effects 0.000 claims abstract description 10
- 230000001678 irradiating effect Effects 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 230000004130 lipolysis Effects 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 15
- 238000002604 ultrasonography Methods 0.000 claims description 13
- 230000036760 body temperature Effects 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 27
- 230000003796 beauty Effects 0.000 abstract description 13
- 235000020824 obesity Nutrition 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 239000007822 coupling agent Substances 0.000 abstract description 2
- 206010018910 Haemolysis Diseases 0.000 description 13
- 210000001789 adipocyte Anatomy 0.000 description 13
- 235000021588 free fatty acids Nutrition 0.000 description 13
- 230000008588 hemolysis Effects 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 210000004003 subcutaneous fat Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000002568 Capsicum frutescens Nutrition 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000000554 physical therapy Methods 0.000 description 3
- 229960004425 sibutramine Drugs 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 241001247145 Sebastes goodei Species 0.000 description 2
- 102000000019 Sterol Esterase Human genes 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- 239000011358 absorbing material Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000032630 lymph circulation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 239000003190 viscoelastic substance Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 210000000636 white adipocyte Anatomy 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 101100478277 Homo sapiens SPTA1 gene Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100037608 Spectrin alpha chain, erythrocytic 1 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000009841 combustion method Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 230000003520 lipogenic effect Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- ZFLBZHXQAMUEFS-KUHUBIRLSA-N methyl 2-[4-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=CC(Cl)=C1 ZFLBZHXQAMUEFS-KUHUBIRLSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
- A61H23/0245—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with ultrasonic transducers, e.g. piezoelectric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
- A61N2007/0008—Destruction of fat cells
Definitions
- Control 8 animals, 11 animals 2 times, 24 KHz 15mWZcm 2 6 animals, 1 MHz 90 OmW / cm 2 12 animals, other frequency and power density were tested for 4 animals each, and the average value and standard error of the multiplication factor b of the value after irradiation with respect to the value before irradiation of FFA were determined (Fig. 1
- the multiplication factor b (FFA value after irradiation // FFA value before irradiation) was plotted in the frequency to power density range of). As can be seen from the figure, there is an effective range in the low frequency range from 15 KHz to 150 KHz and in the high frequency range from 200 KHz to 900 KHz.
- FIG. 1 is an experimental result showing the basis of claims 1 and 2 of the present invention, and shows the lipolysis effectiveness in the frequency to power density range, that is, FFA ⁇ magnification b.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Surgical Instruments (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Abstract
L'invention concerne un agent de décomposition du tissu adipeux utilisant le rayonnement des ondes ultrasonores. Les conditions d'exposition à ce rayonnement sont telles que la densité de puissance sur la surface, exposée au rayonnement, d'un corps à une fréquence ultrasonore de 15-150 kHz n'excède pas 100 mw/cm2, ou bien la densité de puissance à une fréquence ultrasonore de 200-900 kHz n'excède pas le niveau admissible dans le monde médical ultrasonore, sur la base des résultats des expériences menées sur l'innocuité et l'efficacité de la décomposition du tissu adipeux. Cet agent de décomposition s'utilise pour traiter une maladie provoquée par l'obésité, tout en maintenant la santé et la beauté. La formation d'une image de et/ou l'augmentation de température de la partie à exposer au rayonnement est estimée par mesure d'une constante physique d'une onde réfléchie pulsée ultrasonore, ce qui permet de déterminer l'orientation de la partie à exposer au rayonnement et la dose. L'onde ultrasonore émanant d'un oscillateur est appliquée à un jet d'eau ou à une douche, et le jet d'eau résultant est projeté sur le corps, l'exposition au rayonnement étant ainsi ressentie de manière agréable et effectuée aisément. Le produit de décomposition FFA est brûlé par réglage de la température d'un milieu de transmission acoustique, en contact avec le corps, à une valeur inférieure à la température du corps, ou bien par élimination de la chaleur du corps par immersion d'une partie de celui-ci dans de l'eau à 24 °C, pour empêcher le produit de décomposition FFA de redevenir du tissu adipeux. On obtient un effet synergique, dont celui de maintenir un état maigre de la partie exposée au rayonnement, en utilisant un agent de couplage acoustique contenant un agent régulateur de l'obésité ou en exposant au rayonnement d'ondes ultrasonores la partie concernée, pendant une période d'administration d'un agent régulateur de l'obésité.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU57804/98A AU5780498A (en) | 1997-05-26 | 1998-02-05 | Body fat decomposer using ultrasonic waves |
| PCT/JP1998/005032 WO1999039677A1 (fr) | 1998-02-05 | 1998-11-09 | Appareil de rayonnement d'ondes ultrasoniques |
| JP2000530179A JP3416909B2 (ja) | 1998-02-05 | 1998-11-09 | 超音波照射装置 |
| ES98951740T ES2335826T3 (es) | 1998-02-05 | 1998-11-09 | Aparato de irradiacion de ondas ultrasonicas y procedimiento de tratamiento no terapeutico. |
| BRPI9815088-0A BR9815088B1 (pt) | 1998-02-05 | 1998-11-09 | equipamento de sonificaÇço de ultra-som. |
| AU97629/98A AU9762998A (en) | 1998-02-05 | 1998-11-09 | Ultrasonic wave irradiation apparatus |
| KR1020007008542A KR100556060B1 (ko) | 1997-05-26 | 1998-11-09 | 초음파 조사 장치 |
| CA002319583A CA2319583C (fr) | 1998-02-05 | 1998-11-09 | Appareil de sonication aux ultrasons |
| EP98951740A EP1060728B9 (fr) | 1998-02-05 | 1998-11-09 | Appareil de rayonnement d'ondes ultrasoniques et procédé de traitement non thérapeutique |
| CNB988134969A CN1163211C (zh) | 1998-02-05 | 1998-11-09 | 超声波照射设备 |
| US09/600,177 US6450979B1 (en) | 1998-02-05 | 1998-11-09 | Ultrasonic wave irradiation apparatus |
| DE69841275T DE69841275D1 (de) | 1998-02-05 | 1998-11-09 | Bestrahlungsvorrichtung mit ultraschallwellen, sowie nicht-therapeutisches behandlungsverfahren |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9/188968 | 1997-05-26 | ||
| JP18896897 | 1997-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998053787A1 true WO1998053787A1 (fr) | 1998-12-03 |
Family
ID=16233088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1998/000487 WO1998053787A1 (fr) | 1997-05-26 | 1998-02-05 | Agent de decomposition du tissu adipeux utilisant des ondes ultra sonores |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR100556060B1 (fr) |
| AU (1) | AU5780498A (fr) |
| WO (1) | WO1998053787A1 (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004058135A1 (fr) * | 2002-12-24 | 2004-07-15 | Matsushita Electric Works, Ltd. | Attenuateur d'ondes ultrasonores |
| WO2007013546A1 (fr) * | 2005-07-29 | 2007-02-01 | Kabushiki Kaisha Shunkosha | Appareil favorisant l'amaigrissement |
| JP2007516809A (ja) * | 2003-12-30 | 2007-06-28 | ライポソニックス， インコーポレイテッド | 超音波トランスデューサ構成要素 |
| US7347855B2 (en) | 2001-10-29 | 2008-03-25 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
| US7815570B2 (en) | 2001-01-03 | 2010-10-19 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8323220B2 (en) * | 2008-09-19 | 2012-12-04 | Eilaz Babaev | Spider vein treatment apparatus |
| WO2016153199A1 (fr) * | 2015-03-26 | 2016-09-29 | 김지환 | Appareil pour retirer de la graisse et appareil pour séparer des cellules |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03123559A (ja) * | 1989-10-09 | 1991-05-27 | Ya Man Ltd | 超音波美容装置 |
| JPH0521940U (ja) * | 1991-09-04 | 1993-03-23 | 株式会社エステプロ | 超音波細胞活性装置 |
-
1998
- 1998-02-05 AU AU57804/98A patent/AU5780498A/en not_active Abandoned
- 1998-02-05 WO PCT/JP1998/000487 patent/WO1998053787A1/fr active Application Filing
- 1998-11-09 KR KR1020007008542A patent/KR100556060B1/ko not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03123559A (ja) * | 1989-10-09 | 1991-05-27 | Ya Man Ltd | 超音波美容装置 |
| JPH0521940U (ja) * | 1991-09-04 | 1993-03-23 | 株式会社エステプロ | 超音波細胞活性装置 |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7815570B2 (en) | 2001-01-03 | 2010-10-19 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
| US7347855B2 (en) | 2001-10-29 | 2008-03-25 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
| US7875023B2 (en) | 2001-10-29 | 2011-01-25 | Ultrashape Ltd. | Non-invasive ultrasonic body contouring |
| US8454540B2 (en) | 2001-10-29 | 2013-06-04 | Yoram Eshel | Non-invasive ultrasonic body contouring |
| WO2004058135A1 (fr) * | 2002-12-24 | 2004-07-15 | Matsushita Electric Works, Ltd. | Attenuateur d'ondes ultrasonores |
| JP2007516809A (ja) * | 2003-12-30 | 2007-06-28 | ライポソニックス， インコーポレイテッド | 超音波トランスデューサ構成要素 |
| WO2007013546A1 (fr) * | 2005-07-29 | 2007-02-01 | Kabushiki Kaisha Shunkosha | Appareil favorisant l'amaigrissement |
Also Published As
| Publication number | Publication date |
|---|---|
| AU5780498A (en) | 1998-12-30 |
| KR20010040668A (ko) | 2001-05-15 |
| KR100556060B1 (ko) | 2006-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3416909B2 (ja) | 超音波照射装置 | |
| CN107921281B (zh) | 超声波照射装置以及超声波照射系统 | |
| JP4723707B2 (ja) | 痩身器具 | |
| US5413550A (en) | Ultrasound therapy system with automatic dose control | |
| TWI507228B (zh) | 非侵入性破壞脂肪組織並加速脂質代謝之系統 | |
| KR20190040105A (ko) | 초음파 치료 시스템 | |
| WO1998053787A1 (fr) | Agent de decomposition du tissu adipeux utilisant des ondes ultra sonores | |
| US20090171251A1 (en) | Ultrasound treatment of adipose tissue with vacuum feature | |
| CN101410084A (zh) | 用于水磁疗法的方法和实现该方法的装置 | |
| Tran et al. | Effects of contrast agent infusion rates on thresholds for tissue damage produced by single exposures of high-intensity ultrasound | |
| US20090171250A1 (en) | Ultrasound treatment of adipose tissue with fluid injection | |
| RU2289386C2 (ru) | Способ ультразвуковой физиотерапии в жидкости | |
| CA2710675A1 (fr) | Traitement ultrasonore de tissu adipeux presentant une caracteristique de vide | |
| CA2544892C (fr) | Appareil permettant de traiter des patients souffrant de maladies vasculaires au moyen d'ondes infra, audibles et ultrasons | |
| WO2004058135A1 (fr) | Attenuateur d'ondes ultrasonores | |
| Bellomo et al. | The applied mechanical vibration as ultrasound energy | |
| Halachmi et al. | Fundamentals of ultrasound sources | |
| Tbakhi et al. | Design of Therapeutic Ultrasound System for Muscles Pain Treatment | |
| Lioce et al. | Therapeutic Ultrasounds: Physical Basis and Clinical | |
| Baker et al. | A review of therapeutic ultrasound: Biophysical effects | |
| Knoch et al. | Methods of Clinical Application | |
| JP2004065883A (ja) | 超音波を利用した血液、体液活性機 | |
| AHMEDOV et al. | EURASIAN MEDICAL JOURNAL | |
| JP2009028296A (ja) | 洗髪台用ヘッドレスト |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GW HU ID IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |